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Abstract
Introduction There is growing interest in whether social
media can capture patient-generated information relevant
for medicines safety surveillance that cannot be found in
traditional sources.
Objective The aim of this study was to evaluate the
potential contribution of mining social media networks for
medicines safety surveillance using the following associa-
tions as case studies: (1) rosiglitazone and cardiovascular
events (i.e. stroke and myocardial infarction); and (2)
human papilloma virus (HPV) vaccine and infertility.
Methods We collected publicly accessible, English-lan-
guage posts on Facebook, Google?, and Twitter until
September 2014. Data were queried for co-occurrence of
keywords related to the drug/vaccine and event of interest
within a post. Messages were analysed with respect to
geographical distribution, context, linking to other web
content, and author’s assertion regarding the supposed
association.
Results A total of 2537 posts related to rosiglita-
zone/cardiovascular events and 2236 posts related to HPV
vaccine/infertility were retrieved, with the majority of
posts representing data from Twitter (98 and 85 %,
respectively) and originating from users in the US.
Approximately 21 % of rosiglitazone-related posts and
84 % of HPV vaccine-related posts referenced other web
pages, mostly news items, law firms’ websites, or blogs.
Assertion analysis predominantly showed affirmation of
the association of rosiglitazone/cardiovascular events
(72 %; n = 1821) and of HPV vaccine/infertility (79 %;
n = 1758). Only ten posts described personal accounts of
rosiglitazone/cardiovascular adverse event experiences,
and nine posts described HPV vaccine problems related to
infertility.
Conclusions Publicly available data from the considered
social media networks were sparse and largely untrackable
for the purpose of providing early clues of safety concerns
regarding the prespecified case studies. Further research
investigating other case studies and exploring other social
media platforms are necessary to further characterise the
usefulness of social media for safety surveillance.
Key Points
The growing popularity of online communities and
social media networks is stimulating exploration of
these sources for pharmacovigilance purposes.
The potential value of mining data from social
networks appears to be greater for measuring
awareness regarding emerging safety issues.
Further research investigating other case studies
(including prospective investigations) and exploring
other social media platforms are necessary to further
characterise the usefulness of social media for
pharmacovigilance.
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1 Introduction
The past decade has brought forth enormous growth and
popularity of online communities and social networks,
greatly expediting information exchange from one corner
of the world to another. The concept of blogging has
allowed virtually anybody with Internet access to post his
or her views and experiences on any topic at any time.
Whilst the value of such online conversations has been
exploited mostly by commercial enterprises to promote
product improvement and innovation, healthcare has not
been immune to this phenomenon of public engagement
[1–3]. In the same spirit of eliciting greater patient par-
ticipation, several investigators have begun to explore what
social media can offer in terms of medicines safety
surveillance [4–6]. Reporting of individual cases of sus-
pected adverse drug reactions (ADRs) to regulatory
authorities, mostly by physicians or other healthcare pro-
fessionals, remains the cornerstone of pharmacovigilance.
However, spontaneous reporting systems are hampered by
various limitations, the most important of which is under-
reporting [7, 8].
Because social media represent secondary data, i.e. data
that are not originally intended for surveillance, there are
challenges to overcome with respect to terminology,
traceability and reproducibility. Apart from these technical
challenges, practical policy guidelines are lacking on how
potential safety signals from social media should be han-
dled in the current regulatory framework. Although the US
FDA has released two guidance documents on the use of
social media platforms for presenting benefit/risk infor-
mation on prescription drugs and medical devices [9], these
documents are more concerned with product promotion
than surveillance and ‘‘do not establish legally enforceable
rights or responsibilities’’ [10]. The European Medicines
Agency (EMA) guideline on good pharmacovigilance
practices (Module VI) [11] provides provisions on how to
deal with information on suspected adverse reactions from
the Internet or digital media, and hold marketing authori-
sation holders (MAHs) responsible for reviewing websites
under their control for valid cases and reporting them
accordingly, although there is no requirement to trawl
Internet sites not under the control of the MAH. To date,
there are no standard methodologies to mine user-gener-
ated data from social media for pharmacovigilance. In this
study we sought to evaluate the potential contribution of
mining social media networks for pharmacovigilance using
examples of drug–event associations that have been flag-
ged as potential signals: rosiglitazone and cardiovascular
events (i.e. stroke and myocardial infarction), and human
papilloma virus (HPV) vaccine and infertility.
2 Methods
2.1 Data Sources
Postings were collected from three of the most widely used
social media networking platforms (Facebook, Google?,
and Twitter) using their respective search application pro-
gramming interfaces (APIs). The search APIs return a set of
public messages from the social network that match the
query keywords. For each message the content is provided,
together with additional information about the message itself
(date and content), about the status in a conversation (repost
or reply), and about the author (account name and location).
The results are encoded in machine-readable format (Java-
Script Object Notation [JSON]) for integration into custom
application. Messages were obtained from as far back as
available until 25 September 2014. Only English-language
posts were considered. Facebook provides only messages
from the preceding month using their search API, while the
search API of Google? obtains messages dating back to its
establishment in 2011. The search API of Twitter is restricted
to a time window of approximately 1 week. In order to
supplement the Twitter data obtained via its search API, an
additional search engine, Topsy (http://topsy.com/) was
used. Topsy is a real-time search engine for posts and shared
content on social media, primarily on Twitter and Google?.
Topsy has complete coverage of historical messages and has
indexed every (public) tweet ever posted since 2006. As of
this writing, Topsy was a Certified Reseller of Twitter’s data.
For this particular study, only Twitter-related posts were
retrieved via the free analytics service of Topsy.com. No
Facebook or Google? posts were retrieved in Topsy.
2.2 Case Studies
Usefulness of the above social media platforms for safety
surveillance was evaluated using two examples of drug–
adverse event associations that have previously been flag-
ged as potential safety signals: (1) rosiglitazone and car-
diovascular events (i.e. stroke and myocardial infarction);
and (2) HPV vaccine and infertility. These two case studies
were chosen because they represent associations that have
triggered controversies and thus are likely to have been the
subject of media attention as well as online discussions.
Furthermore, the case studies involve different types of
agents that are used by different subsets of the population
under different circumstances, thus allowing investigation
of diverse scenarios.
For each case study, data were queried for co-occur-
rence of the drug/vaccine of interest and the event of
interest within the same post or tweet. Search queries were
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constructed using all possible drug–event keyword com-
binations (the keywords used are provided in the Appendix,
available as electronic supplementary material). Event-re-
lated keywords consisted of clinical terms from the Unified
Medical Language System (UMLS), as well as known
abbreviations and layman’s terms (see Appendix). Drug-
related keywords consisted of international nonproprietary
names and trade names.
2.3 Assessment of Suitability for Use in Safety
Surveillance
Relevant posts were tallied and analysed with respect to
geographical distribution, context, and linking to other web
content. The country of origin of a message was auto-
matically determined from the location information about
the author. When the country was not available in a des-
ignated data field, it was manually identified from the
available location information by means of a list of names
of countries, regions and cities. The frequency of message
propagation (i.e. reposts or retweets) was calculated. The
content of all posts were reviewed one by one to determine
whether there was reference to a person’s actual experience
of having the (adverse) event of interest in relation to
exposure to the drug (or vaccine) of interest. It was not the
intention to assign or assess causality, but rather to describe
the context of how the drug–event relationship is described.
Posts were likewise analysed with respect to the author’s
assertion of the purported association between the drug (or
vaccine) of interest and the event of interest. Somewhat
analogous to sentiment analysis, assertion was judged as
one of the following: (1) ‘affirmative’, if the post alluded to
an affirmation of the association; (2) ‘negating’, if the post
alluded to a negation of the association; or (3) ‘neutral’, if
the post alluded to neither affirmation nor negation of the
association. Manual review and annotation of the assertions
was undertaken by a physician/pharmacist (PMC). In
addition, key dates during which important communication
or regulatory actions occurred were marked and compared
with the timeline of the posts.
3 Results
3.1 Rosiglitazone and Cardiovascular Events
As shown in Table 1, we retrieved a total of 2537 posts
related to rosiglitazone and cardiovascular events (i.e.
stroke and myocardial infarction), with the overwhelming
majority of posts (98 %) representing data from Twitter.
Only two posts were retrieved on Facebook, while 41 posts
were retrieved on Google?. Approximately 10 % of all
posts were reposts or retweets. The country of origin (based
on the holder of the social network account) could not be
automatically identified in 59 % of the posts; of the posts
that could be identified, two-thirds were accounted for by
the US, while the remaining one-third was distributed
among 50 other countries or territories all over the world.
Overall, 21 % of posts (n = 536) had links to other web
pages (see Table 2). News items comprised more than one-
third of the web pages referenced (n = 196), followed by
law firms’ websites or advertisements (n = 157) and blogs
(n = 138). There were 24 posts referring to health infor-
mation websites intended for health professionals, 15 posts
linking to scientific journals, four posts referring to a
patient community website, one post linking to a hospital’s
patient education website, and another linking to a You-
Tube video.
Assertion analysis carried out on all posts predominantly
demonstrated affirmation of the association between
rosiglitazone and cardiovascular events (72 %; n = 1821),
with the remainder more or less split between negating
(13 %) and neutral (15 %). Most neutral posts were asking
for further information or were otherwise not directly
related to the drug–adverse event association. There were
posts by lawyers or reporters explicitly soliciting cases
(n = 12), but there were also posts (n = 122) ridiculing
lawyers’ television commercials that asked patients who
‘died while taking the drug’ to call a particular number.
Figure 1 shows the trend of assertions over time in relation
to events in the timeline of the association of interest. The
highest peak of affirmative posts occurred in February
2010. In this particular month, the US Senate Finance
Committee released a report based on a 2-year inquiry of
rosiglitazone, expressing concern that the ‘‘FDA has
overlooked or overridden safety concerns cited by its own
officials’’ [12]. The EMA’s suspension of rosiglitazone’s
marketing authorisation in the EU, and the FDA’s restric-
tion of access to the drug, coincided with the second peak
of affirmative posts in September 2010, while the simul-
taneous publication in high-impact journals of two studies
demonstrating increased cardiovascular risk with the use of
rosiglitazone [13, 14] coincided with the peak in June
2010. The peaks in negating assertions paralleled those of
the affirmative, with the greatest peak in affirmations
observed in June–July 2010 (and a smaller peak in
November 2013), reflecting the active online debate that
was happening regarding the issue. Figure 1 also shows
that in June 2013, negating posts actually outnumbered the
affirmative posts; the results of the FDA-mandated re-
evaluation of the rosiglitazone (RECORD) trial [15]
became available online in June 2013. The peak of neutral
posts seen in July 2011 represented posts about news of
rosiglitazone being potentially useful for neuropathic pain
(although the pertinent study [16] had already been pub-
lished online 3 months earlier).
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There were only ten posts that appeared to be about
experiences of the drug–adverse event association of
interest. Four posts involved the person posting the mes-
sage himself or herself (one even claimed winning a legal
case against the drug manufacturer); three involved
somebody’s brother-in-law, while there was one each for
somebody’s father, father-in-law, and grandmother. In
addition, two posts referenced a patient community website
that claimed 21,015 people reported to have had a heart
attack while taking rosiglitazone (representing ‘32 % of all
who reported side effects’). Interestingly, some posts
(n = 20) alleged other adverse events of rosiglitazone,
such as leg pain, abdominal pain and eye pain (all of which
are symptoms suggestive of end-organ complications of
diabetes, the primary indication for the drug), while others
(n = 67) alluded to a beneficial effect of the drug (pre-
vention of neuropathic pain).
3.2 HPV Vaccine and Infertility
A total of 2236 posts related to HPV vaccine and infertility
were retrieved, again with the majority of posts (85 %)
representing data from Twitter (see Table 3). There were
23 posts on Facebook, while 308 posts were retrieved on
Google?. Reposts or retweets comprised 23 % of all posts.
Similar to posts related to the previous case study on
rosiglitazone, the country of origin was unknown for more
than half of the HPV vaccine-related posts, with the US
representing the majority (n = 567) of those posts that
could be automatically identified. However, in contrast to
the rosiglitazone-related posts, a large proportion of all
posts (84 %) referenced other web pages (see Table 4).
Various blogs comprised almost half of the linked web
pages referenced (n = 872), followed by news items
(n = 669) and scientific journals (n = 118). Most of the
Table 1 Overview of posts about rosiglitazone and cardiovascular adverse events across social media networking platforms
Social media
platform
No. of
posts (%)
No. of
reposts (%)
No. of posts with links
to other sites (%)
Earliest/latest date
of retrieved post
Origin of post (country,
based on account holder)a
Facebook 2 (0.1) 0 2 (100) July 2014/August 2014 US (1)
Unknown (1)
Google? 41 (1.6) 6 (15) 41 (100) June 2012/August 2014 Unknown (31)
US (9)
Egypt (1)
Twitter 2494 (98.3) 250 (10) 493 (20) May 2007/September 2014 Unknown (1461)
US (682)
India (53)
UK, Canada (50 each)
Indonesia (31)
Other countries (167)
Total 2537 256 (10) 536 (21)
a Where applicable, only the top five countries are given
Table 2 Description of web pages referenced by posts about rosiglitazone and cardiovascular events
Category of linked web pages Facebook
[n = 2] (%)
Google?
[n = 41] (%)
Twitter
[n = 493] (%)
Total
[n = 536] (%)
News – 8 (20) 188 (38) 196 (37)
Law firm’s website or advertisement 1 (50) 17 (41) 139 (28) 157 (29)
Blog – 13 (32) 125 (25) 138 (26)
Health reference for professionals – 2 (5) 22 (5) 24 (5)
Patient community website – – 4 (1) 4 (\1)
Health education for patients 1 (50) – – 1 (\1)
Scientific journal – – 15 (3) 15 (3)
Video – 1 (2) – 1 (\1)
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blogs commented on these same news items or journal
articles. There were 112 posts referring to health infor-
mation websites intended for health professionals and 49
posts linking to (mostly antivaccine) YouTube videos,
while only a minority of posts were associated with law-
yer’s websites or advertisements (n = 24).
The posts demonstrated predominantly affirmative
assertion of the association between HPV vaccine and
infertility (79 %; n = 1758), with posts that negate the
association accounting for 4 % (n = 85) and neutral posts
accounting for the rest. Most neutral posts were asking for
further information (particularly with use of the vaccine
Fig. 1 Trend of assertions of
rosiglitazone/cardiovascular
event-related posts over time.
EMA European Medicines
Agency, EU European Union,
FDA Food and Drug
Administration
Table 3 Overview of posts about HPV vaccine and infertility across social media networking platforms
Social media
platform
No. of
posts (%)
No. of
reposts (%)
No. of posts with links
to other sites (%)
Earliest/latest date
of retrieved post
Origin of post (country,
based on account holder)a
Facebook 23 (1) 6 (26) 15 (65) April 2014/September 2014 Unknown (19)
Bangladesh, India,
The Philippines, US (1 each)
Google? 308 (14) 67 (22) 286 (93) September 2011/September 2014 Unknown (197)
US (61)
Canada (7)
Australia, India (6 each)
UK (4)
Other countries (27)
Twitter 1905 (85) 437 (23) 1570 (82) July 2008/September 2014 Unknown (1059)
US (505)
Canada (112)
Australia (40)
UK (38)
Italy, Egypt (10 each)
Other countries (131)
Total 2236 510 (23) 1871 (84)
a Where applicable, only the top five countries are given
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during pregnancy), were related to cervical cancer aware-
ness, or were negative comments about the HPV vaccine in
general but not directly related to infertility. Figure 2
shows the trend of assertions over time in relation to events
in the timeline of the association of interest. The highest
peak of affirmative posts occurred in November 2013 when
two sisters, aged 20 and 19 years, alleged at a US federal
court that Gardasil (trade name of the HPV vaccine) caused
them to go into early menopause and become infertile. The
build-up to this peak appears to have been triggered by a
study describing three young women who presented with
secondary amenorrhea following HPV vaccination [17];
this study was first published online at the end of July 2013
(corresponding to the earlier, but smaller, peak in Fig. 2).
Many of the posts within the period from August to
October 2013 actually referred to an event that happened
1 year before—the publication of the first case report on the
association of interest. This case report of a 16-year-old
Australian girl who had premature ovarian failure after HPV
vaccination was first published online in October 2012 [18].
There were nine posts that appeared to be accounts of
HPV vaccine–adverse event experience. Six posts involved
the person posting the message herself. One simply said
she was ‘15 and infertile’ because of the vaccine (the actual
page appears to have been taken down after the initial data
collection), while four other individuals claimed to have an
ovarian cyst, delayed period (and negative pregnancy test),
(vaginal) spotting, menopause and hot flashes because of
the vaccine. One post was about somebody’s friend who
was ‘21 and infertile due to the HPV vaccine’ and there
Table 4 Description of web pages referenced by posts about human papilloma virus vaccine and infertility
Category of linked web pages Facebook
[n = 15] (%)
Google?
[n = 286] (%)
Twitter
[n = 1570] (%)
Total
[n = 1871] (%)
News 4 (27) 126 (44) 539 (34) 669 (36)
Law firm’s website or advertisement – 3 (1) 21 (1) 24 (1)
Blog 5 (33) 111 (39) 756 (48) 872 (47)
Health reference for professionals – 8 (3) 104 (7) 112 (6)
Scientific journal – 1 (\1) 117 (7) 118 (6)
Video 1 (7) 16 (6) 32 (2) 49 (3)
Multiple sites, including health education 5 (33) 21 (7) 1 (\1) 27 (1)
Fig. 2 Trend of assertions of
HPV vaccine/infertility-related
posts over time. HPV human
papilloma virus
926 P. M. Coloma et al.
were two posts from different mothers whose daughters
had no (menstrual) periods after receiving the vaccine.
4 Discussion
In this study, we aimed to characterise the data currently
available from social media networking platforms and to
determine if, and how, such data can be tapped for
surveillance of two specific safety issues: rosiglitazone and
cardiovascular events (i.e. stroke and myocardial infarc-
tion), and HPV vaccine and infertility. Rosiglitazone is a
drug indicated for a very prevalent disease (diabetes), and
although such a disease is expected to occur in the middle-
aged population (who comprise a relative minority of the
population of Twitter users), it was precisely one of the
aims of this study to illustrate that such a group and such a
condition of interest could be underrepresented in social
media networks, however huge these networks may be. The
primary motivation for exploring social media as an addi-
tional resource for pharmacovigilance is to capture infor-
mation that cannot be found in traditional sources. Among
the three websites evaluated, Twitter provided the greatest
number of (publicly available) posts potentially relevant to
the two case studies, but these mostly represented links to
news items or, particularly for rosiglitazone and cardio-
vascular events, websites of personal injury lawyers rather
than accounts of drug/vaccine-related adverse events. The
ubiquity and instantaneous nature of the Internet and social
media networks supposedly provides a mechanism to find
adverse drug (or vaccine, or medical device) experiences of
laymen that are otherwise missed by ADR reporting sys-
tems, and in real time. Thus, one of the more relevant
questions to ask is whether data from social media net-
works can provide early signs of potential safety concerns.
Despite the hype about social media representing ‘big
data’, the volume of relevant posts was sparse for the two
case studies considered. Although Twitter has over
500 million users (more than half of whom are reportedly
active), it was too ‘young’ a source to use, particularly for
the case study on rosiglitazone. When the FDA issued the
safety alert on Avandia in May 2007, Twitter had only
been in service for less than 1 year, was largely in its trial
phase, and thus still had few subscribers. The same argu-
ment can be said for Facebook, which became available in
September 2006, and Google?, which was launched much
later in September 2011. The problem that these social
media sites did not have enough time to accumulate data
should have been less of an issue for the HPV vaccine–
infertility association, which is a more recent potential
safety concern, yet that does not seem to be the case.
Our findings corroborate what other researchers have
shown regarding the geographic distribution of users of
social media networks: a small number of countries, led by
the US, account for a large share of the total user popu-
lation and likewise make up the active and influential user
population [19, 20] (see also http://www.beevolve.com/
twitter-statistics/). Although this is not totally unexpected,
given that only English-language posts were obtained in
this study, there can be implications on inferences drawn
from research using data from social media networks.
There were (only) 10 and 9 accounts of adverse expe-
riences related to rosiglitazone/cardiovascular events and
HPV vaccine/infertility, respectively, but these experiences
appeared to be more reactionary than anticipatory (mean-
ing they were shared online after news about the safety
issues broke out). Furthermore, verification of such alle-
gations proved to be difficult considering the data privacy
constraints (only publicly accessible data could be anal-
ysed) and, in particular, establishing an identifiable patient
and ‘reporter’ (required for valid safety reporting in tradi-
tional pharmacovigilance systems) is challenging, if not
impossible. The scenario of unprincipled individuals
spreading inaccurate, and even false, information is not
unheard of [21], and since social media is largely unreg-
ulated, cannot be avoided. Interestingly, two posts identi-
fied in the current study referenced a health information
and community website that claims to have studied (as of
the time of writing this article) ‘‘65,460 people who have
side effects while taking Avandia from FDA and social
media’’, and among them, 21,015 had a ‘heart attack’
(http://www.ehealthme.com/ds/avandia/heart?attack). In
addition, there were 7752 people who had a ‘stroke’ (http://
www.ehealthme.com/ds/avandia/stroke). The website pro-
vides statistics on when the heart attack/stroke was repor-
ted, age and sex of people who had a heart attack/stroke
when taking Avandia, ‘time on Avandia when people have
a heart attack/stroke’, ‘severity of the heart attack/stroke
when taking Avandia’, ‘top conditions involved for these
people’, and ‘top co-used drugs for these people’. All such
information, if truthful, are relevant. However, nowhere is
it stated which part of the information comes from social
media and specifically from which social media (there are
too many of them). More importantly, there is no
description of how these reports were obtained, the actual
configuration and content of the reports could not be
traced, and the circumstances surrounding the alleged
adverse events could not be verified. While the site does
include a general disclaimer and a counsel to ‘report
adverse side effects to the FDA’, these sections are found at
the end of the page and may be easily ignored.
White et al. [22] utilised retrospective web search logs
to make a case for Internet users providing early clues
about adverse drug events via their online information
seeking. Chary et al. proposed tools for using data from
social networks to characterise patterns of (recreational)
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drug abuse [23], while Harpaz et al. provided an extensive
review on how state-of-the-art text mining for adverse drug
events can leverage unstructured data sources, including
social media [24]. Similar to the current study, Freifeld
et al. used publicly available data from Twitter to obtain
messages that resembled adverse event reports (‘proto-
AEs’) related to 23 prespecified medical products [5].
Rather than focusing on a few specific events of interest,
the Freifeld et al. study collected all potential events
(symptoms), thus resulting in more permutations of search
terms, which explains why their study had a higher yield of
relevant posts compared with our study. While our current
study was more of a ‘scoping’ study across three social
media networking platforms for two specific case studies,
the study by Freifeld et al. had a different aim—to evaluate
concordance between Twitter posts mentioning AE-like
reactions and spontaneous reports received by the FDA
Adverse Event Reporting System. There is the implicit
assumption of an equivalent level of information between
the two sources, which, among other things, necessitated
the development of a dictionary to map Internet vernacular
to the standardised ontology, Medical Dictionary for
Regulatory Activities (MedDRA). Other researchers have
explored the utility of more specific health-oriented web-
sites and patient community forums to identify adverse
drug events [25] and to better understand the impact of
ADRs [26]. These types of social media sources are likely
to provide more relevant content because their very nature
allows for sharing of health-related concerns among
patients with similar conditions (‘like me’) and would
make verification easier since user registration is often
mandatory and more exhaustive (the likelihood of faking
an illness in this group is probably lower). Personal
accounts of adverse events from such sources are often
inaccessible to the public, although many of the prominent
and moderated patient community websites will allow
access to further information under certain conditions of
use (and sometimes for a fee). These more health-oriented
social media platforms are certainly worth exploring,
especially for surveillance of uncommon adverse events, as
well as those related to drugs indicated for rare conditions.
The potential value of mining data from social networks
appears to be greatest for measuring awareness regarding
potential safety concerns. Because this study focused only
on English-language posts, there is the caveat that the
findings are biased towards users from English-speaking
countries, particularly the US, which comprise the majority
of subscribers of these social networking sites. Both
number of posts and assertion trend in the two case studies
were predominantly driven by events that occurred in the
US. Another caveat is that bad news is often more popular
than good news. The case report of the 16-year-old girl
from Australia who had premature ovarian failure after
HPV vaccination fired up huge comments online, while
four studies (published earlier or around the same time)
[27–30] that showed no evidence of increased risk for new
adverse events, including those related to fertility, were
practically ignored.
The other, perhaps even more relevant, question to ask is
whether data from social media networks can be used to
help corroborate, or refute, potential safety concerns by
providing information where there is none. It is time to turn
the impressionability of social media as an advantage and
leverage it towards bringing balanced and evidence-based
information to the Internet and its multitude of users.
Our study has several limitations. Data were queried for
co-occurrence of the drug/vaccine of interest and the event
of interest within the same post or tweet, which may have
limited the number of relevant posts obtained. Similarly,
the use of publicly available data and English-language-
only posts may have contributed to sampling bias. The
assertion analysis conducted may not always reflect the
true opinion of the user, the very nature of social media
promoting an open and unrestricted environment. A gen-
eralisation cannot be made as to which among the social
networking platforms provides the most valuable infor-
mation since the amount and nature of commentaries
generated and shared within each network is a function of
its own culture and privacy restrictions. Moreover, the
population of users of social networking sites comprises the
relatively young (and healthy) and fairly educated who
have access to the Internet [31–33]. The evaluation
undertaken was retrospective and the findings for these
particular case studies considered may not necessarily
reflect discussions about safety concerns related to other
drugs or other vaccines in the future. Because social media
platforms are continually being re-engineered to improve
the commercial service, there is the concern as to whether
studies conducted on data collected from these platforms
are reproducible, even 1 year later [34]. The phenomenon
of ‘blue team dynamics’ has been described where the
algorithm generating the data (and, consequently, user
utilisation) has been modified by service providers such as
Google, Twitter and Facebook in line with their business
model [34, 35]. Similarly, there are the so-called ‘red team’
dynamics, which occur when social media platform users
attempt to manipulate the data-generating process to sup-
port their own economic or political gain [34, 36].
5 Conclusions
Publicly available data from the considered social media
networks were sparse and largely untrackable for the pur-
pose of providing early clues of safety concerns regarding
the prespecified case studies (rosiglitazone and stroke/
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myocardial infarction, and HPV vaccine and infertility).
The potential value of mining data from social networks
appears to be greater for measuring awareness regarding
emerging safety issues, with the caveat that this will be
biased towards a younger and healthier population who
comprise the majority of subscribers of these social net-
working sites. Further research investigating other case
studies (including prospective investigations) and explor-
ing other social media platforms are necessary to further
characterise the usefulness of social media for postmar-
keting safety surveillance.
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